Prelude Therapeutics Incorporated
NASDAQ:PRLDBiotechnology
-$0.14 today
- Market cap
- $191.00M
- Beta
- 1.01
- P/E (TTM)
- -4.5
- EPS (TTM)
- -$0.94
Volume 0.23M
Average 0.38M
PRLD Sales of Investments
Cash received from selling or redeeming investments.
Prelude Therapeutics IncorporatedNASDAQ: PRLD
Sales of Investments · Q1 FY2026 · quarter ended Mar 2026
Sales of investments declines year over year
Q1 FY2026 sales of investments of $8.5M fell 88.1% year over year, behind the -48.9% change in trailing-twelve-month sales of investments. Sequentially, it rose 32.8% from the prior quarter. Over 3 fiscal years it compounded at -8.9% a year.
Context
- Sales of investments amounted to 1271.8% of revenue in FY2025, down 780.4 pp from a year earlier.
- Sales of investments increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -88.1% toward the trailing-twelve-month pace of -48.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Sales of Investments history
USD · from the cash flow
- Latest · FY2025
- 154.39M USD
- Year-over-year change
- +7.5%
| Period | Period end | Sales of Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 154.39M | +7.5% |
| FY2024 | 2024-12-31 | 143.65M | -24.6% |
| FY2023 | 2023-12-31 | 190.5M | -6.6% |
| FY2022 | 2022-12-31 | 203.93M | — |
| FY2021 | 2021-12-31 | 0 | — |
Sales of Investments vs competitors
How PRLD compares with its peers on the latest reported figures
- Peers report in different currencies, so sales of investments is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -48.9% is the 7th highest of 9, against a peer median of -19.0%.
- Sales of investments amounts to 545.4% of revenue for PRLD, versus a peer median of 1217.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $287.42M USD | +13.1% | +4.8% | 415.3% | |
| LTM Mar 2026 | $233.37M USD | +44.8% | — | 1684.0% | |
| LTM Mar 2026 | $233.02M USD | -36.4% | -0.0% | 2080.0% | |
| LTM Mar 2026 | $212M USD | -16.7% | +13.5% | 751.1% | |
| LTM Mar 2026 | $91.2M USD | -48.9% | -8.9% | 545.4% | |
| LTM Mar 2026 | $57.47M USD | -21.3% | — | 175.6% | |
| LTM Mar 2026 | $46.7M USD | — | — | 79155.9% | |
| LTM Mar 2026 | $34.02M USD | -63.1% | -38.6% | 15118.2% | |
| LTM Mar 2026 | $9M USD | -14.3% | — | — | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | $0 USD | — | — | — |
| FY2025 | €0 EUR | -100.0% | — | 0.0% | |
| Peer median (excluding PRLD) | — | -19.0% | +2.4% | 1217.6% | |
Competitors are the stored peer set for PRLD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (111.69M) | (115.44M) | (121.83M) | (127.17M) | (99.5M) |
| Depreciation & Amortization | 915K | 1.32M | 1.17M | 1.77M | 1.34M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 20.93M | 25.14M | 25.62M | 21.35M | 11.91M |
| Change in Working Capital | 3.63M | 932K | (10.48M) | 4.22M | 28.41M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 3.9M | (347K) | (2.27M) | 3.31M | (3.92M) |
| Other Working Capital | (278K) | 1.28M | (8.21M) | 911K | 32.33M |
| Other Non-Cash Items | 2.69M | 4.31M | (1.54M) | (3.05M) | 1.53M |
| Operating Cash Flow | (83.53M) | (83.73M) | (107.06M) | (102.89M) | (56.3M) |
| Capital Expenditures | (2.32M) | (3.02M) | (3.51M) | (764K) | (67K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (261.48M) | (119.22M) | (221.63M) | (52.69M) | (100.87M) |
| Sales of Investments | 0 | 203.93M | 190.5M | 143.65M | 154.39M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (263.8M) | 81.69M | (34.65M) | 90.19M | 53.46M |
| Debt Repayment | 0 | 0 | 0 | (395K) | (208K) |
| Common Stock Issued | 161.42M | 815K | 135.73M | 329K | 25.04M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.47M | 0 | 664K | (54K) | (17K) |
| Financing Cash Flow | 164.9M | 815K | 136.4M | (120K) | 24.82M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (182.44M) | (1.22M) | (5.31M) | (12.82M) | 21.97M |
| Free Cash Flow | (85.85M) | (86.75M) | (110.58M) | (103.65M) | (56.37M) |
Prelude Therapeutics Incorporated
NASDAQ:PRLD
Intrinsic Alpha fair value
Locked
Current Price
$3.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.